The Lilly Endowment, principal stakeholder in Eli Lilly & Co. (NYSE:LLY), has seen its assets grow to $60 billion, largely due to the success of Eli Lilly's weight-loss drug, Mounjaro. Eli Lilly's stock rose nearly 60% in the past year, enabling the endowment to increase its philanthropic giving to $2 billion in 2023. This growth brings the endowment closer to the Gates Foundation in terms of assets. However, analysts express concerns about the sustainability of the stock's performance in 2024 due to potential competition and valuation issues. The Lilly Endowment focuses on Indiana-based and religious organizations, operating independently from Eli Lilly despite shared board members.